Lessons learned in adjuvant colorectal cancer

Theresa Schmalfuß; Hossein Taghizadeh

doi:10.1007/s12254-023-00882-5

Lessons learned in adjuvant colorectal cancer

Division of Internal Medicine 1 (University Hospital St. Pölten)

Research output: Journal article (peer-reviewed) › Review article

1 Citation (Scopus)

Abstract

Colorectal cancer (CRC) is one of the most frequent malignancies. While adjuvant fluoropyrimidine-based chemotherapy has been established as standard of care for patients with stage III disease, its value and role are still uncertain for stage II disease. This review discusses the usefulness of adjuvant therapy in both stages and highlights the use of liquid biopsy via circulating tumor DNA (ctDNA) for the assessment of minimal residual disease which will shape the therapy decision for adjuvant treatment in future.

Original language	English
Pages (from-to)	113-115
Number of pages	3
Journal	Memo - Magazine of European Medical Oncology
Volume	16
Issue number	2
DOIs	https://doi.org/10.1007/s12254-023-00882-5
Publication status	Published - Jun 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s12254-023-00882-5

https://link.springer.com/10.1007/s12254-023-00882-5

Cite this

@article{dd61cd93dbbe45f693f8b2e8d3700850,

title = "Lessons learned in adjuvant colorectal cancer",

abstract = "Colorectal cancer (CRC) is one of the most frequent malignancies. While adjuvant fluoropyrimidine-based chemotherapy has been established as standard of care for patients with stage III disease, its value and role are still uncertain for stage II disease. This review discusses the usefulness of adjuvant therapy in both stages and highlights the use of liquid biopsy via circulating tumor DNA (ctDNA) for the assessment of minimal residual disease which will shape the therapy decision for adjuvant treatment in future.",

author = "Theresa Schmalfu{\ss} and Hossein Taghizadeh",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = jun,

doi = "10.1007/s12254-023-00882-5",

language = "English",

volume = "16",

pages = "113--115",

journal = "Memo - Magazine of European Medical Oncology",

issn = "1865-5041",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Lessons learned in adjuvant colorectal cancer

AU - Schmalfuß, Theresa

AU - Taghizadeh, Hossein

PY - 2023/6

Y1 - 2023/6

N2 - Colorectal cancer (CRC) is one of the most frequent malignancies. While adjuvant fluoropyrimidine-based chemotherapy has been established as standard of care for patients with stage III disease, its value and role are still uncertain for stage II disease. This review discusses the usefulness of adjuvant therapy in both stages and highlights the use of liquid biopsy via circulating tumor DNA (ctDNA) for the assessment of minimal residual disease which will shape the therapy decision for adjuvant treatment in future.

AB - Colorectal cancer (CRC) is one of the most frequent malignancies. While adjuvant fluoropyrimidine-based chemotherapy has been established as standard of care for patients with stage III disease, its value and role are still uncertain for stage II disease. This review discusses the usefulness of adjuvant therapy in both stages and highlights the use of liquid biopsy via circulating tumor DNA (ctDNA) for the assessment of minimal residual disease which will shape the therapy decision for adjuvant treatment in future.

UR - https://www.scopus.com/pages/publications/85153747489

U2 - 10.1007/s12254-023-00882-5

DO - 10.1007/s12254-023-00882-5

M3 - Review article

SN - 1865-5041

VL - 16

SP - 113

EP - 115

JO - Memo - Magazine of European Medical Oncology

JF - Memo - Magazine of European Medical Oncology

IS - 2

ER -

Lessons learned in adjuvant colorectal cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this